New combo targets tricky lung cancer transformation after TKI failure
NCT ID NCT07001995
First seen Mar 26, 2026 · Last updated Apr 30, 2026 · Updated 4 times
Summary
This study tests a combination of limertinib plus chemotherapy (carboplatin and etoposide) in 30 adults with a specific type of lung cancer (EGFR-mutant NSCLC) that has transformed into small cell lung cancer after initial targeted therapy stopped working. The goal is to see if this new treatment can control the cancer longer. Participants must have had prior EGFR-TKI treatment and biopsy-confirmed transformation.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Yongchang Zhang
Changsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.